Búsqueda | Portal de Búsqueda de la BVS

1.

ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.

Ledermann, J A; Matias-Guiu, X; Amant, F; Concin, N; Davidson, B; Fotopoulou, C; González-Martin, A; Gourley, C; Leary, A; Lorusso, D; Banerjee, S; Chiva, L; Cibula, D; Colombo, N; Croce, S; Eriksson, A G; Falandry, C; Fischerova, D; Harter, P; Joly, F; Lazaro, C; Lok, C; Mahner, S; Marmé, F; Marth, C; McCluggage, W G; McNeish, I A; Morice, P; Nicum, S; Oaknin, A; Pérez-Fidalgo, J A; Pignata, S; Ramirez, P T; Ray-Coquard, I; Romero, I; Scambia, G; Sehouli, J; Shapira-Frommer, R; Sundar, S; Tan, D S P; Taskiran, C; van Driel, W J; Vergote, I; Planchamp, F; Sessa, C; Fagotti, A.

Ann Oncol ; 35(3): 248-266, 2024 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-38307807

2.

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.

Frenel, J S; Kim, J W; Aryal, N; Asher, R; Berton, D; Vidal, L; Pautier, P; Ledermann, J A; Penson, R T; Oza, A M; Korach, J; Huzarski, T; Pignata, S; Colombo, N; Park-Simon, T W; Tamura, K; Sonke, G S; Freimund, A E; Lee, C K; Pujade-Lauraine, E.

Ann Oncol ; 33(10): 1021-1028, 2022 10.

Artículo en Inglés | MEDLINE | ID: mdl-35772665

3.

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.

Poveda, A; Lheureux, S; Colombo, N; Cibula, D; Lindemann, K; Weberpals, J; Bjurberg, M; Oaknin, A; Sikorska, M; González-Martín, A; Madry, R; Pérez, M J Rubio; Ledermann, J; Davidson, R; Blakeley, C; Bennett, J; Barnicle, A; Skof, E.

Gynecol Oncol ; 164(3): 498-504, 2022 03.

Artículo en Inglés | MEDLINE | ID: mdl-35063276

4.

The systemic treatment of recurrent ovarian cancer revisited.

Baert, T; Ferrero, A; Sehouli, J; O'Donnell, D M; González-Martín, A; Joly, F; van der Velden, J; Blecharz, P; Tan, D S P; Querleu, D; Colombo, N; du Bois, A; Ledermann, J A.

Ann Oncol ; 32(6): 710-725, 2021 06.

Artículo en Inglés | MEDLINE | ID: mdl-33675937

5.

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.

Miller, R E; Leary, A; Scott, C L; Serra, V; Lord, C J; Bowtell, D; Chang, D K; Garsed, D W; Jonkers, J; Ledermann, J A; Nik-Zainal, S; Ray-Coquard, I; Shah, S P; Matias-Guiu, X; Swisher, E M; Yates, L R.

Ann Oncol ; 31(12): 1606-1622, 2020 12.

Artículo en Inglés | MEDLINE | ID: mdl-33004253

6.

A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.

Hall, M R; Dehbi, H-M; Banerjee, S; Lord, R; Clamp, A; Ledermann, J A; Nicum, S; Lilleywhite, R; Bowen, R; Michael, A; Feeney, A; Glasspool, R; Hackshaw, A; Rustin, G.

Gynecol Oncol ; 159(3): 692-698, 2020 12.

Artículo en Inglés | MEDLINE | ID: mdl-33077258

7.

Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).

Roncolato, F T; O'Connell, R L; Joly, F; Lanceley, A; Hilpert, F; Buizen, L; Okamoto, A; Aotani, E; Salutari, V; Donnellan, P; Oza, A; Avall-Lundqvist, E; Berek, J; Fehm, T; Ledermann, J; Roemer-Becuwe, C; Stockler, M R; King, M T; Friedlander, M L.

Gynecol Oncol ; 156(1): 45-53, 2020 01.

Artículo en Inglés | MEDLINE | ID: mdl-31836184

8.

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.

Mirza, Mansoor R; Benigno, B; Dørum, A; Mahner, S; Bessette, P; Barceló, I Bover; Berton-Rigaud, D; Ledermann, J A; Rimel, B J; Herrstedt, J; Lau, S; du Bois, A; Herráez, A Casado; Kalbacher, E; Buscema, J; Lorusso, D; Vergote, I; Levy, T; Wang, P; de Jong, F A; Gupta, D; Matulonis, U A.

Gynecol Oncol ; 159(2): 442-448, 2020 11.

Artículo en Inglés | MEDLINE | ID: mdl-32981695

9.

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.

Colombo, N; Sessa, C; du Bois, A; Ledermann, J; McCluggage, W G; McNeish, I; Morice, P; Pignata, S; Ray-Coquard, I; Vergote, I; Baert, T; Belaroussi, I; Dashora, A; Olbrecht, S; Planchamp, F; Querleu, D.

Ann Oncol ; 30(5): 672-705, 2019 05 01.

Artículo en Inglés | MEDLINE | ID: mdl-31046081

10.

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

Matulonis, U A; Shapira-Frommer, R; Santin, A D; Lisyanskaya, A S; Pignata, S; Vergote, I; Raspagliesi, F; Sonke, G S; Birrer, M; Provencher, D M; Sehouli, J; Colombo, N; González-Martín, A; Oaknin, A; Ottevanger, P B; Rudaitis, V; Katchar, K; Wu, H; Keefe, S; Ruman, J; Ledermann, J A.

Ann Oncol ; 30(7): 1080-1087, 2019 07 01.

Artículo en Inglés | MEDLINE | ID: mdl-31046082

11.

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.

Colombo, N; Sessa, C; Bois, A du; Ledermann, J; McCluggage, W G; McNeish, I; Morice, P; Pignata, S; Ray-Coquard, I; Vergote, I; Baert, T; Belaroussi, I; Dashora, A; Olbrecht, S; Planchamp, F; Querleu, D.

Int J Gynecol Cancer ; 2019 05 02.

Artículo en Inglés | MEDLINE | ID: mdl-31048403

12.

Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.

Mirza, M R; Pignata, S; Ledermann, J A.

Ann Oncol ; 29(6): 1366-1376, 2018 06 01.

Artículo en Inglés | MEDLINE | ID: mdl-29750420

13.

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

González-Martín, A; Harter, P; Leary, A; Lorusso, D; Miller, R E; Pothuri, B; Ray-Coquard, I; Tan, D S P; Bellet, E; Oaknin, A; Ledermann, J A.

Ann Oncol ; 34(10): 833-848, 2023 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-37597580

14.

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.

Sessa, C; Balmaña, J; Bober, S L; Cardoso, M J; Colombo, N; Curigliano, G; Domchek, S M; Evans, D G; Fischerova, D; Harbeck, N; Kuhl, C; Lemley, B; Levy-Lahad, E; Lambertini, M; Ledermann, J A; Loibl, S; Phillips, K-A; Paluch-Shimon, S.

Ann Oncol ; 34(1): 33-47, 2023 01.

Artículo en Inglés | MEDLINE | ID: mdl-36307055

15.

OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.

Provencher, D M; Gallagher, C J; Parulekar, W R; Ledermann, J A; Armstrong, D K; Brundage, M; Gourley, C; Romero, I; Gonzalez-Martin, A; Feeney, M; Bessette, P; Hall, M; Weberpals, J I; Hall, G; Lau, S K; Gauthier, P; Fung-Kee-Fung, M; Eisenhauer, E A; Winch, C; Tu, D; MacKay, H J.

Ann Oncol ; 29(2): 431-438, 2018 02 01.

Artículo en Inglés | MEDLINE | ID: mdl-29186319

16.

Safety and dose modification for patients receiving niraparib.

Berek, J S; Matulonis, U A; Peen, U; Ghatage, P; Mahner, S; Redondo, A; Lesoin, A; Colombo, N; Vergote, I; Rosengarten, O; Ledermann, J; Pineda, M; Ellard, S; Sehouli, J; Gonzalez-Martin, A; Berton-Rigaud, D; Madry, R; Reinthaller, A; Hazard, S; Guo, W; Mirza, M R.

Ann Oncol ; 29(8): 1784-1792, 2018 08 01.

Artículo en Inglés | MEDLINE | ID: mdl-29767688

17.

Front-line therapy of advanced ovarian cancer: new approaches.

Ledermann, J A.

Ann Oncol ; 28(suppl_8): viii46-viii50, 2017 Nov 01.

Artículo en Inglés | MEDLINE | ID: mdl-29232475

18.

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Oaknin, A; Bosse, T J; Creutzberg, C L; Giornelli, G; Harter, P; Joly, F; Lorusso, D; Marth, C; Makker, V; Mirza, M R; Ledermann, J A; Colombo, N.

Ann Oncol ; 33(9): 860-877, 2022 09.

Artículo en Inglés | MEDLINE | ID: mdl-35690222

19.

Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.

Bookman, M A; Okamoto, A; Stuart, G; Yanaihara, N; Aoki, D; Bacon, M; Fujiwara, K; González-Martín, A; Harter, P; Kim, J W; Ledermann, J; Pujade-Lauraine, E; Quinn, M; Ochiai, K.

Ann Oncol ; 28(suppl_8): viii30-viii35, 2017 Nov 01.

Artículo en Inglés | MEDLINE | ID: mdl-29232472

20.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.

Karam, A; Ledermann, J A; Kim, J-W; Sehouli, J; Lu, K; Gourley, C; Katsumata, N; Burger, R A; Nam, B-H; Bacon, M; Ng, C; Pfisterer, J; Bekkers, R L M; Casado Herráez, A; Redondo, A; Fujiwara, H; Gleeson, N; Rosengarten, O; Scambia, G; Zhu, J; Okamoto, A; Stuart, G; Ochiai, K.

Ann Oncol ; 28(4): 711-717, 2017 Apr 01.

Artículo en Inglés | MEDLINE | ID: mdl-28327917

Portal de Búsqueda de la BVS

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.

The systemic treatment of recurrent ovarian cancer revisited.

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.

A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.

Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.

Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.

OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.

Safety and dose modification for patients receiving niraparib.

Front-line therapy of advanced ovarian cancer: new approaches.

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.